
Conference Coverage
26 days ago
Is Pharma Moving Too Fast on AI Agents?Latest Content

Executive Conversations: Where Traditional Channel Models Break Down

UPS to Acquire Smartways Logistics, Expanding APAC Health Care Reach

Trump Pulls Overton's FDA Nomination Ahead of Senate HELP Vote

Executive Conversations: Why Channel Design Should Start With the Patient

How Retrofitting Idle US Plants Could Speed Drug Reshoring

Shorts










Podcasts
All News

In Episode 1, Part 4, Jon Hamrick, Rena Goins and Bob Cochran explain what separates trade teams seen as strategic partners from those that aren't.

Fragmented data is eroding trust in pharma insights, and AI raises the stakes. A four-step approach can help organizations pay down their “data debt.”

Thani Jambulingam, Ph.D., says MFN pricing, Section 232 tariffs and PBM reform will converge to shape how pharma launches and commercializes new drugs.

In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold storage line, and FDA adds a NAION warning across the GLP-1 class.

In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.

In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.

CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

APIIC's Brian Doty says renovating shuttered US plants with advanced manufacturing is faster and cheaper than building new to reshore generics.

Joint clinical assessment, shifting HTA demands and pricing pressure are making launch the start of continuous evidence generation.

APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.















